HomeXBIT • NASDAQ
XBiotech Inc
Follow
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 8.75M | 1.87% |
Net income | -10.51M | -126.71% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -8.31M | -1.91% |
Effective tax rate | 0.39% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 172.68M | -13.67% |
Total assets | 199.09M | -12.14% |
Total liabilities | 16.83M | 116.57% |
Total equity | 182.27M | — |
Shares outstanding | 30.49M | — |
Price to book | 0.49 | — |
Return on assets | -10.70% | — |
Return on capital | -11.08% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -10.51M | -126.71% |
Cash from operations | -6.54M | -90.50% |
Cash from investing | -84.00K | 26.96% |
Cash from financing | 283.00K | — |
Net change in cash | -10.44M | -381.60% |
Free cash flow | -5.72M | -88.39% |
Previous close
$2.95
Day range
$2.65 - $3.00
Year range
$2.65 - $9.96
Market cap
87.50M USD
Avg Volume
45.67K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases. Wikipedia
Founded
2005
Headquarters
Website
Employees
92
